Nitroxides, Oxyamines Or Hydroxylamines (i.e., N-o Or N-oh) Patents (Class 514/645)
  • Patent number: 9822106
    Abstract: The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 21, 2017
    Assignee: CELTAXSYS, INC.
    Inventors: William Guilford, David Davey
  • Patent number: 9695119
    Abstract: Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: July 4, 2017
    Assignee: Bioxiness Pharmaceuticals, Inc.
    Inventors: Mansour Bassiri, Afsaneh Rahimi-Larijani
  • Patent number: 9034355
    Abstract: A polymeric composition capable of releasing nitric oxide and modulating biological responses comprises a biocompatible polymer and S-nitrosated thiol bonded to the biocompatible polymer. The polymeric composition can have a thiol conversion of at least 40%. The polymeric composition can also have a nitric oxide recovery of at least 40% when under thermal decomposition conditions.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: May 19, 2015
    Assignee: Colorado State University Research Foundation
    Inventors: Melissa M. Reynolds, Vinod B. Damodaran
  • Patent number: 9034926
    Abstract: Psoriasis is treated by application of a composition containing a nitrone spin trap such as ?-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and method of treatments further comprise at least one adjunctive ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate, and polyenylphosphatidylcholine.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: May 19, 2015
    Inventor: Nicholas V. Perricone
  • Patent number: 8969313
    Abstract: The invention relates to a method of preventing, inhibiting, arresting or reversing tumorigenesis in a cell as well as a method of inducing apoptosis in a tumor cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also provided is a pharmaceutical composition that comprises a compound of general formula (I), wherein A is CH or N, R1, R4 and R5 are independent from each other H, an aliphatic group, an alicyclic group, an aromatic group, an arylaliphatic group, and an arylalicyclic group comprising 0-3 heteroatoms. The heteroatoms may be N, O, S, or Si. R4 and R5 may optionally be linked so as to define an aliphatic hydrocarbyl bridge. R2 is H or a halogen such as F, Cl, Br or L. R3 is H, F, Cl or an aliphatic or arylaliphatic group that includes 1-8 main chain carbon atoms and 0-3 heteroatoms. The pharmaceutical composition also comprises a histone deacetylase inhibitor.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: March 3, 2015
    Assignee: Agency for Science, Technology and Research
    Inventor: Qiang Yu
  • Patent number: 8853277
    Abstract: The invention provides therapeutic methods that include administering a stable nitroxide to a subject that has, is suspected to have, or is at risk for having a condition associated with reduced VHL or elevated HIF-2?.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 7, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: W. Marston Linehan, Tracey A. Rouault, James Mitchell, Murali K. Cherukuri
  • Publication number: 20140275166
    Abstract: Spin-traps and spin labels and their reduction products are claimed for the treatment of peri- and post-menopausal syndrome.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 18, 2014
    Inventor: Peter Herbert Proctor
  • Patent number: 8829051
    Abstract: One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: September 9, 2014
    Inventors: Geoffrey C. Gurtner, Michael A. Brownlee
  • Publication number: 20140249161
    Abstract: Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring.
    Type: Application
    Filed: February 27, 2014
    Publication date: September 4, 2014
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: David WATT, Chunming LIU, Vitaliy M. SVIRIPA, Wen ZHANG
  • Patent number: 8822541
    Abstract: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: September 2, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Natalia A. Belikova, Jianfei Jiang, Joshua Pierce, Joel Greenberger, Michael Epperly, Valerian Kagan
  • Patent number: 8822540
    Abstract: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3 or OCA4 genes, by administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound (2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione), also known as NTBC for a sufficient period of time. The administration of NTBC is believed to increase the amount of pigmentation in the subject and alleviate certain symptoms caused by lack of pigmentation in the eye tissues. Also described are methods of use of NTBC for increasing the pigmentation of a subject for cosmetic purposes, by administering to the subject a therapeutically effective amount of NTBC.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: September 2, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Brian P. Brooks, William A. Gahl
  • Patent number: 8802120
    Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 12, 2014
    Assignee: Sciessent LLC
    Inventor: Joseph J. Crudden
  • Patent number: 8772346
    Abstract: The present invention relates to a pharmaceutical composition of practically water insoluble or low water soluble compounds containing catechol moiety by enhancing the solubility of such compounds using one or more alkalizing agent and optionally adding one or more pharmaceutically acceptable excipient. The present invention also relates to a process for preparing such pharmaceutical composition.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: July 8, 2014
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Samanta Gour, Nanda Nagesh
  • Patent number: 8748369
    Abstract: Provided herein are compositions and related methods useful for accelerating bone healing and growth. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: June 10, 2014
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Michael W. Epperly, Abhay Sudhir Gokhale, Joel S. Greenberger, Peter Wipf, Julianne Glowacki
  • Publication number: 20140148513
    Abstract: The invention provides methods of inhibiting the development or progression of a thioesterase deficiency disorder in a mammal by the administration of a compound that functionally mimics the enzymatic activity of all thioesterases in mammals. Such thioesterase deficiency disorders include cancers and adult- or infant-neuronal ceroid lipofuscinoses (NCLs). The invention also provides small molecule mimics of thioesterases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds and methods of using the same.
    Type: Application
    Filed: April 9, 2012
    Publication date: May 29, 2014
    Applicants: DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anil Baran Mukherjee, Chinmoy Sarkar, Zhongjian Zhang
  • Patent number: 8716346
    Abstract: This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: May 6, 2014
    Assignee: Case Western Reserve University
    Inventors: Stanton Gerson, Lili Liu
  • Publication number: 20140107071
    Abstract: Provided according to some embodiments of the invention are methods of manufacturing a pharmaceutical composition. In some embodiments, such methods include homogenizing at a first excipient composition that includes a viscosity agent and at least one solvent to form a first premix composition; separately homogenizing at least one active pharmaceutical ingredient (API) and a second excipient composition to form a second premix composition; and combining the first premix composition and the second premix composition to form the composition. The pre-mixing of constituents may increase the stability of the API and provide uniformity of the dispersion of the constituents throughout the final topical composition.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: Novan, Inc.
    Inventors: Eleftherios Kougoulos, Nathan Stasko
  • Patent number: 8664250
    Abstract: A wood treatment composition having a synergistic combination of fungicides which may include two or more compounds. These combinations are shown to be especially effective in providing resistance to decay, mold and mildew when wood is treated with these combinations. Also provided is wood treated by these combinations, and a method of treatment for composite wood.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: March 4, 2014
    Assignee: Kop-Coat, Inc.
    Inventors: Alan S. Ross, Brian Marks, Hans Ward
  • Patent number: 8653065
    Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: February 18, 2014
    Assignee: Pisgah Laboratories, Inc.
    Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
  • Publication number: 20140011761
    Abstract: Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA) has been shown to reduce ER stress is TSC-deficient cells. Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide arid glycerol may also be useful in treating tuberous sclerosis. The present invention provides methods of treating a subject suffering from tuberous sclerosis using ER stress reducers such as PBA, TUDCA, UDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in TSC-deficient cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating tuberous sclerosis.
    Type: Application
    Filed: December 20, 2012
    Publication date: January 9, 2014
    Applicant: President and Fellows of Harvard College
    Inventors: Gokhan S. Hotamisligil, Umut Ozcan, Brendan D. Manning
  • Publication number: 20130316906
    Abstract: The invention relates to novel compounds of the formula (I) in which R1, R2, R3, R4, R5, Y, Q and G have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as herbicides and/or pesticides. Moreover, the invention relates to selective herbicidal compositions comprising, firstly, the phenyl-substituted bicyclooctane-1,3-dione derivates and, secondly, a crop plant compatibility-improving compound. The present invention furthermore relates to increasing the activity of crop protection compositions comprising in particular phenyl-substituted bicyclooctane-1,3-dione derivates by adding ammonium salts or phosphonium salts and, if appropriate, penetrants, to the corresponding compositions, to processes for their preparation and to their use in crop protection as pesticides and/or for preventing unwanted plant growth.
    Type: Application
    Filed: October 28, 2011
    Publication date: November 28, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Alfred Angermann, Stefan Lehr, Guido Bojack, Reiner Fischer, Isolde Häuser-hahn, Ines Heinemann, Elmar Gatzweiler, Christopher Hugh Rosinger, Arnd Voerste, Dieter Feucht
  • Patent number: 8592485
    Abstract: The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: November 26, 2013
    Assignee: HealthPartners Research Foundation
    Inventors: Leah Ranae Bresin Hanson, William H. Frey, II
  • Patent number: 8580859
    Abstract: Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and unit dosages.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: November 12, 2013
    Assignee: BioXiness Pharmaceuticals, Inc.
    Inventors: Mansour Bassiri, Afsaneh Rahimi-Larijani
  • Patent number: 8552068
    Abstract: Gaseous nitric oxide (NO) can be delivered to a mammal for prophylactic or therapeutic purposes using a composition capable of delivering NO, comprising a compound capable of forming a reversible bond or association with NO. Methods for the manufacture and use of said composition are disclosed.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: October 8, 2013
    Inventors: Per Agvald, Dag Linnarsson, Christofer Adding, Lars Gustafsson, Kristofer Nilsson
  • Publication number: 20130217673
    Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of mixed monoamine reuptake inhibitor locally at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least thirty days. In some embodiments, the relief can be for at least at least fifty days, at least one hundred days, at least one hundred and twenty days, at least one hundred and thirty, at least one hundred fifty days or at least one hundred and eighty days.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 22, 2013
    Applicant: Warsaw Orthopedic, Inc
    Inventor: Jared T. Wilsey
  • Patent number: 8466130
    Abstract: The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: June 18, 2013
    Assignees: Colby Pharmaceutical Company, Medical College of Wisconsin, Inc.
    Inventors: David A. Zarling, Hirak S. Basu, Balaraman Kalyanaraman, Joy Joseph
  • Patent number: 8410175
    Abstract: An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric oxide donor is an effective ingredient. In accordance with the present invention, an excellent therapeutic effect is able to be achieved on non-small cell lung cancer which is still in such a state that no effective therapeutic method has been established yet for a progressive cancer which is not operable and is one of cancers where chemotherapy is most difficult to apply.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: April 2, 2013
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Hiroyasu Yasuda, Mutsuo Yamaya, Katsutoshi Nakayama, Hidetada Sasaki
  • Patent number: 8372830
    Abstract: The present invention relates to methods of reducing cardiotoxicity and/or improving survival from treatment with anthracycline agents comprising administering a therapeutically effective amount of a composition comprising a vasopressin antagonist compound or a pharmaceutically acceptable salt thereof as an active ingredient, administered simultaneously or prior to the anthracycline administration.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: February 12, 2013
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Yongge Liu, Junichi Kambayashi
  • Publication number: 20130030237
    Abstract: Provided herein are pharmaceutical compositions and methods of treating cancer wherein the cytotoxic activity of an anticancer agent is potentiated by the combination of base excision repair (BER) pathway inhibitors.
    Type: Application
    Filed: April 15, 2011
    Publication date: January 31, 2013
    Inventor: Charles Theuer
  • Patent number: 8354451
    Abstract: Methods of inhibiting phagolysosomal fusion in patients infected with a microorganism involve the administration of a 4-hydroxyphenylpyruvate dioxygenase (HPPD)-inhibiting compound, such as 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) to the patient. A HPPD-inhibiting compound administered in an amount effective to enhance phagolysosomal fusion in the macrophages or neutrophils of the patient reduces or treats the infection. Methods for treating bacterial infections by administering a HPPD-inhibiting compound and reducing the production of pyomelanin or melanin in microorganisms are disclosed.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: January 15, 2013
    Assignee: The UWM Research Foundation, Inc.
    Inventors: Graham R. Moran, Panqing He
  • Patent number: 8324282
    Abstract: This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: December 4, 2012
    Assignee: Case Western Reserve University
    Inventors: Stanton L. Gerson, Lili Liu
  • Publication number: 20120282255
    Abstract: The present invention provides for compositions and methods for treating or preventing addictive and compulsive diseases and disorders, particular alcohol-related diseases and disorders, disclosed herein. The GLP activators of the present invention are effective against various alcohol and drug dependency diseases. In accordance with the invention, the present compositions and methods can be used to intercede upstream or downstream in the signal transduction cascade involved in GLP action to treat various alcohol and drug dependency diseases. In one embodiment, the synthesis or release of endogenous GLP can be stimulated. In another embodiment, the endogenous synthesis or release of another molecule active in the cascade downstream from GLP, (e.g., a molecule produced in response to GLP binding to a receptor), can be stimulated.
    Type: Application
    Filed: April 6, 2012
    Publication date: November 8, 2012
    Inventor: Greg Plucinski
  • Publication number: 20120270917
    Abstract: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.
    Type: Application
    Filed: July 30, 2010
    Publication date: October 25, 2012
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: William F. DeGrado, Jun Wang
  • Patent number: 8287893
    Abstract: Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: October 16, 2012
    Assignee: Sciessent LLC
    Inventor: Joseph J. Crudden
  • Patent number: 8273769
    Abstract: The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: September 25, 2012
    Assignee: Merck Serono SA
    Inventors: Stefano Crosignani, Catherine Jorand-Lebrun, Christophe Cleva, Adeline Pretre
  • Patent number: 8268890
    Abstract: Nitroxyl donating compounds are administered prior to the onset of ischemia for the prevention and/or reduction of ischemia/reperfusion injury in subjects at risk for ischemia. Nitroxyl donors also are administered to organs to be transplanted for the prevention and/or reduction of ischemia/reperfusion injury upon reperfusion in a recipient. Nitroxyl donors include any nitroxyl donating compound. In particular cases the nitroxyl donor is a nitroxyl-donating diazeniumdiolate, such as Angeli's salt or IPA/NO.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: September 18, 2012
    Assignees: Johns Hopkins University, The United States of America as represented by the Secretary of Health and Human Services, The Regents of the University of California
    Inventors: David A. Wink, Martin Feelisch, Pasquale Pagliaro, David A. Kass, Nazareno Paolocci, Katrina M. Miranda, Jon M. Fukuto
  • Publication number: 20120201907
    Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 9, 2012
    Applicants: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Johns Hopkins University, The Regents of the University of California, Government of the USA represented by the Secretary of the Department of Health and Human Services
    Inventors: David A. WINK, Martin FEELISCH, David A. KASS, Nazareno PAOLOCCI, Katrina MIRANDA, Jon FUKUTO, Tatsuo KATORI
  • Patent number: 8236334
    Abstract: Disclosed is a method for protecting a tree from insects by injecting the tree with a fungicide and/or an antibiotic, and applying a composition to the surface of the tree, said composition comprising water, an insect repellent, an antihistamine, and an insect poison.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: August 7, 2012
    Inventor: James S. Bass
  • Publication number: 20120196874
    Abstract: Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. The halogenated stilbene analogs include nitrogen heteroaryl groups and/or amino groups on the stilbene ring.
    Type: Application
    Filed: January 27, 2012
    Publication date: August 2, 2012
    Inventors: David WATT, Chunming Liu, Vitaliy M. Sviripa, Wen Zhang
  • Publication number: 20120184625
    Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.
    Type: Application
    Filed: March 27, 2012
    Publication date: July 19, 2012
    Applicants: University of Western Sydney, Bioprospect Limited
    Inventors: Robert Neil Spooner-Hart, Albert Habib Basta
  • Publication number: 20120171158
    Abstract: The present invention relates to methods for the treatment of infection, a disease, or a condition using CD26 (DPIV) inhibitors. The present invention also relates to an antibody that binds to the IP-10 protein and a method of monitoring the necessity for administering a CD26 inhibitor to a patient, comprising evaluating a level of sIP-10, a activity of CD26, and/or a level of CXCR3 cells in a sample.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 5, 2012
    Applicant: INSTITUT PASTEUR
    Inventors: Matthew Albert, Armanda Casrouge, Jeremie Decalf, Stanislas Pol, Arnaud Fontanet, Mostafa Mohamed
  • Patent number: 8153741
    Abstract: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: April 10, 2012
    Assignee: Tyco Healthcare Group LP
    Inventor: Joshua B. Stopek
  • Publication number: 20120065145
    Abstract: This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.
    Type: Application
    Filed: July 22, 2011
    Publication date: March 15, 2012
    Inventors: Stanton L. Gerson, Lili Liu
  • Publication number: 20120021055
    Abstract: The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.
    Type: Application
    Filed: June 24, 2011
    Publication date: January 26, 2012
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Jae Ho Shin, Nathan Stasko
  • Publication number: 20110301036
    Abstract: Materials and methods for the formation of microcapsules that include a high concentration of agriculturally active ingredients (AIs) and a lipophilic polymer encapsulated within a polymeric shell formed via an interfacial polycondensation reaction. Under some conditions, these microcapsules may be formed using less lipophilic solvent than is required using convention microencapsulation techniques. These inventive methods include forming an oil-in-water emulsion in some cases using a first polymer as a lipophilic solvent for the AI and forming a microcapsule that includes the AI and polymer. Other methods include forming a microcapsule that includes a lipophilic monomer, agriculturally active ingredient and initiator having a polymeric shell then elevating the temperature to initiate polymerization of the monomer with the microcapsule.
    Type: Application
    Filed: April 11, 2011
    Publication date: December 8, 2011
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Holger Tank, Wen Xu
  • Patent number: 8067464
    Abstract: The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound, and, optionally, at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating gastrointestinal disorders; (h) treating inflammatory disorders; and (j) treating respiratory disorders; and (k) treating peripheral vascular diseases. The apocynin compound may preferably be apocynin.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: November 29, 2011
    Assignee: Nitromed, Inc.
    Inventor: David S. Garvey
  • Publication number: 20110275645
    Abstract: The invention provides compounds that inhibit protein kinases, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and/or prodrugs, pharmaceutical compositions including the compounds and/or prodrugs and methods of using the compounds and/or prodrugs in a variety of contexts, including, for example, in the treatment and/or prevention of various diseases that are responsive to protein kinase inhibition and/or that are mediated, at least in part, by inappropriate kinase activity.
    Type: Application
    Filed: May 5, 2010
    Publication date: November 10, 2011
    Inventors: Renee Desai, Ketan Desai
  • Patent number: 8017618
    Abstract: Compositions and methods useful in the treatment of certain cancers. The methods include administering, to a patient receiving an antifolate anticancer agent, methoxyamine administered in an amount sufficient to enhance or increase the effect of the antifolate anticancer agent. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: September 13, 2011
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Charles P. Theuer, Bonne Jean Adams
  • Publication number: 20110218158
    Abstract: Cytosine deaminase inhibitors and methods for identifying inhibitors of the anti-retroviral activity of APOBEC3G are described.
    Type: Application
    Filed: September 22, 2009
    Publication date: September 8, 2011
    Inventors: Reuben S. Harris, Ming Li
  • Patent number: 7999051
    Abstract: The present disclosure provides copolymers including a first monomer including at least one phospholipid possessing at least one vinyl group and a second monomer including a furanone possessing vinyl and/or acrylate groups. Compositions, medical devices, and coatings including such copolymers are also provided.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: August 16, 2011
    Assignee: Tyco Healthcare Group LP
    Inventor: Joshua B. Stopek